Background and Objectives: In recent years, the effectiveness of chemotherapy after
immune checkpoint inhibitor administration has attracted attention in various cancers …

Objectives The benefit of sequential therapy after immune checkpoint inhibitor (ICI)
treatment for recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC) …

6038 Background: Immune checkpoint inhibitors (ICI) are currently approved in the
treatment of patients (pts) with recurrent-metastatic (R/M) head and neck squamous cell …

Background After the introduction of ICI treatment, data about feasibility and activity of a
cetuximab-containing first-line therapy in patients with recurrent and/or metastatic head and …

Objectives To examine the impact of treatment sequences of Immune checkpoint inhibitor
(ICI) and cetuximab on clinical outcomes in patients with recurrent or metastatic (R/M) head …

Objectives To evaluate the efficacy and safety of immune checkpoint inhibitor (ICI)
combination therapy in the first-line treatment for recurrent or metastatic squamous cell …

Objective Immune checkpoint inhibitors (ICI) have become widely used becuse of their
effectiveness and relatively low rate of severe adverse events. However, active treatment …

6036 Background: Salvage chemotherapy after progression on immune checkpoint
inhibitors (ICIs) was associated with an objective response rate (ORR) of 30% in patients …

Background Immune checkpoint inhibitors (ICI) are active in patients with
recurrent/metastatic squamous cell carcinoma of the head and neck (R/M SCCHN). Recent …

Immunotherapy has been shown to prolong survival in recurrent or metastatic squamous cell
carcinoma of the head and neck (SCCHN) in front-line use; however, subsequent systemic …